Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$10.10
+0.7%
$10.58
$3.52
$23.40
$461.14M0.821.97 million shs758,397 shs
InnovAge Holding Corp. stock logo
INNV
InnovAge
$4.43
+6.7%
$3.80
$2.60
$6.69
$598.09M0.5150,643 shs29,140 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.34
+5.2%
$1.46
$0.85
$4.42
$61.07M1.21471,591 shs141,463 shs
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
$0.14
$0.14
$0.06
$3.80
$4.20M2.671.87 million shs13.32 million shs
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
$0.00
$0.00
$0.00
$0.00
$79K4.89N/AN/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
0.00%-9.46%-29.06%+9.97%+109.88%
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.00%+13.01%+10.20%+45.72%-13.14%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.00%-5.25%-20.95%+38.70%-57.18%
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
0.00%0.00%0.00%+450.00%+10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.3483 of 5 stars
4.63.00.00.02.00.80.6
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.6382 of 5 stars
1.82.00.00.00.01.70.6
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.326 of 5 stars
3.74.00.00.02.30.00.0
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.11
Buy$32.22219.19% Upside
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.50
Reduce$5.0012.87% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00573.65% Upside
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
0.00
N/AN/AN/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PDSB, INNV, SNNA, CAPR, and WCUI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/30/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
6/26/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $29.00
6/24/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00
6/23/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$43.00 ➝ $22.00
6/17/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/13/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
5/20/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$31.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M20.71N/AN/A$3.20 per share3.15
InnovAge Holding Corp. stock logo
INNV
InnovAge
$763.85M0.78N/AN/A$2.04 per share2.17
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.51 per shareN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/A$1.27 per shareN/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
$660K0.12N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$40.47M-$1.42N/AN/AN/A-181.71%-62.42%-48.36%8/6/2025 (Estimated)
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$21.34M-$0.23N/A73.83N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
-$73.47M-$3.59N/AN/AN/AN/A-177.36%-52.22%N/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
-$750KN/A0.00N/AN/AN/AN/AN/A

Latest PDSB, INNV, SNNA, CAPR, and WCUI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
5/13/2025Q1 2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million
5/6/2025Q3 2025
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/A
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
6.55
6.55
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.04
0.78
0.78
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.29
2.33
2.33
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/A
15.27
15.27
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
17.36%
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10145.68 million40.88 millionOptionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,350135.01 million133.12 millionOptionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2045.71 million41.51 millionOptionable
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
3930.91 millionN/ANot Optionable
Wellness Center Usa Inc. stock logo
WCUI
Wellness Center Usa
8143.19 million120.71 millionNot Optionable

Recent News About These Companies

Cancer Wellness Center of NEPA holds Annual Walk
Wellness Center attendance up
MCCTC Plans New Health and Wellness Center

New MarketBeat Followers Over Time

Media Sentiment Over Time

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$10.10 +0.08 (+0.75%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$10.18 +0.08 (+0.84%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

InnovAge stock logo

InnovAge NASDAQ:INNV

$4.43 +0.28 (+6.75%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$4.73 +0.30 (+6.75%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.34 +0.07 (+5.20%)
Closing price 07/3/2025 03:46 PM Eastern
Extended Trading
$1.35 +0.01 (+1.05%)
As of 04:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Sienna Biopharmaceuticals stock logo

Sienna Biopharmaceuticals NASDAQ:SNNA

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Wellness Center Usa stock logo

Wellness Center Usa OTCMKTS:WCUI

$0.0006 0.00 (0.00%)
As of 07/3/2025

Wellness Center USA, Inc. engages in the healthcare and medical business in the United States and internationally. The company operates through Medical Devices; and Authentication and Encryption Products and Services segments. It is primarily involved in the marketing and distribution of online sports and nutrition supplements. The company also designs, develops, manufactures, markets, and distributes targeted ultraviolet phototherapy devices that include Psoria-Light, which is used in targeted PUVA photochemistry and UVB phototherapy for the treatment of skin conditions, such as psoriasis, vitiligo, atopic dermatitis, seborrheic dermatitis, and leukoderma. In addition, it offers intelligent microparticles, which provide technologies within the security and supply chain management vertical sectors; and ActiveDuty, a data intelligence service comprising proprietary, unprecedented, and actionable technology, which include a suite of analytical tools, such as artificial intelligence and social psychology for industries, companies, and agencies. The company was incorporated in 2010 and is based in Tucson, Arizona.